OrganoClick Future Growth
Future criteria checks 4/6
OrganoClick is forecast to grow earnings and revenue by 105.8% and 11.8% per annum respectively. EPS is expected to grow by 105.9% per annum. Return on equity is forecast to be 16.2% in 3 years.
Key information
105.8%
Earnings growth rate
105.9%
EPS growth rate
Chemicals earnings growth | 10.1% |
Revenue growth rate | 11.8% |
Future return on equity | 16.2% |
Analyst coverage | Low |
Last updated | 06 Nov 2024 |
Recent future growth updates
Earnings Release: Here's Why Analysts Cut Their OrganoClick AB (publ) (STO:ORGC) Price Target To kr3.00
May 03Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their Forecasts
Feb 18Recent updates
A Piece Of The Puzzle Missing From OrganoClick AB (publ)'s (STO:ORGC) 26% Share Price Climb
Jun 19Shareholders May Find It Hard To Justify Increasing OrganoClick AB (publ)'s (STO:ORGC) CEO Compensation For Now
May 09Earnings Release: Here's Why Analysts Cut Their OrganoClick AB (publ) (STO:ORGC) Price Target To kr3.00
May 03Sentiment Still Eluding OrganoClick AB (publ) (STO:ORGC)
Mar 25Earnings Update: OrganoClick AB (publ) (STO:ORGC) Just Reported And Analysts Are Trimming Their Forecasts
Feb 18OrganoClick (STO:ORGC) Seems To Use Debt Quite Sensibly
Jan 09Is OrganoClick AB (publ) (STO:ORGC) Potentially Undervalued?
May 11There's No Escaping OrganoClick AB (publ)'s (STO:ORGC) Muted Revenues Despite A 33% Share Price Rise
Apr 18Here's Why OrganoClick (STO:ORGC) Can Afford Some Debt
Jan 25Does OrganoClick (STO:ORGC) Have A Healthy Balance Sheet?
Sep 21OrganoClick AB (publ) (STO:ORGC) Just Reported Earnings, And Analysts Cut Their Target Price
Feb 21Health Check: How Prudently Does OrganoClick (STO:ORGC) Use Debt?
Feb 20Is OrganoClick (STO:ORGC) Weighed On By Its Debt Load?
Apr 20Loss-Making OrganoClick AB (publ) (STO:ORGC) Expected To Breakeven In The Medium-Term
Mar 23Should You Take Comfort From Insider Transactions At OrganoClick AB (publ) (STO:ORGC)?
Feb 12What Percentage Of OrganoClick AB (publ) (STO:ORGC) Shares Do Insiders Own?
Jan 05Analysts Expect Breakeven For OrganoClick AB (publ) (STO:ORGC) Before Long
Dec 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 170 | 7 | 3 | 17 | 1 |
12/31/2025 | 147 | -2 | 2 | 11 | 1 |
12/31/2024 | 130 | -18 | -9 | -1 | 1 |
9/30/2024 | 134 | -18 | -4 | 6 | N/A |
6/30/2024 | 138 | -17 | -1 | 8 | N/A |
3/31/2024 | 141 | -17 | -3 | 5 | N/A |
12/31/2023 | 146 | -16 | -8 | 1 | N/A |
9/30/2023 | 140 | -28 | -13 | -6 | N/A |
6/30/2023 | 128 | -33 | -14 | -4 | N/A |
3/31/2023 | 126 | -40 | -31 | -20 | N/A |
12/31/2022 | 115 | -44 | -35 | -21 | N/A |
9/30/2022 | 111 | -36 | -48 | -33 | N/A |
6/30/2022 | 112 | -35 | -51 | -37 | N/A |
3/31/2022 | 113 | -32 | -51 | -36 | N/A |
12/31/2021 | 110 | -33 | -52 | -38 | N/A |
9/30/2021 | 110 | -31 | -37 | -21 | N/A |
6/30/2021 | 108 | -29 | -40 | -17 | N/A |
3/31/2021 | 104 | -24 | -31 | -9 | N/A |
12/31/2020 | 96 | -24 | -14 | 5 | N/A |
9/30/2020 | 93 | -23 | -27 | -9 | N/A |
6/30/2020 | 89 | -23 | -19 | -11 | N/A |
3/31/2020 | 86 | -23 | -21 | -12 | N/A |
12/31/2019 | 85 | -20 | -18 | -11 | N/A |
9/30/2019 | 84 | -18 | -11 | -5 | N/A |
6/30/2019 | 84 | -18 | -12 | -7 | N/A |
3/31/2019 | 82 | -18 | -12 | -8 | N/A |
12/31/2018 | 78 | -20 | -24 | -19 | N/A |
9/30/2018 | 78 | -23 | -27 | -21 | N/A |
6/30/2018 | 78 | -24 | N/A | -31 | N/A |
3/31/2018 | 75 | -26 | N/A | -29 | N/A |
12/31/2017 | 75 | -28 | N/A | -23 | N/A |
9/30/2017 | 69 | -26 | N/A | -19 | N/A |
6/30/2017 | 62 | -26 | N/A | -17 | N/A |
3/31/2017 | 51 | -28 | N/A | -18 | N/A |
12/31/2016 | 40 | -29 | N/A | -16 | N/A |
9/30/2016 | 38 | -28 | N/A | -19 | N/A |
6/30/2016 | 37 | -25 | N/A | -13 | N/A |
3/31/2016 | 33 | -22 | N/A | -18 | N/A |
12/31/2015 | 32 | -20 | N/A | -24 | N/A |
9/30/2015 | 30 | -17 | N/A | -20 | N/A |
6/30/2015 | 27 | -16 | N/A | -17 | N/A |
3/31/2015 | 24 | -16 | N/A | -16 | N/A |
12/31/2014 | 21 | -16 | N/A | -17 | N/A |
9/30/2014 | 20 | -15 | N/A | -30 | N/A |
12/31/2013 | 8 | -9 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORGC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: ORGC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ORGC is expected to become profitable in the next 3 years.
Revenue vs Market: ORGC's revenue (11.8% per year) is forecast to grow faster than the Swedish market (-0.02% per year).
High Growth Revenue: ORGC's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORGC's Return on Equity is forecast to be low in 3 years time (16.2%).